Search PubMed⌕ Search

Biomedical subjects

P Irwin

Publications and source records attributed to P Irwin.

At least 55 records · Page 3Linked to original sources

Pharmacoelectroencephalographic study of brotizolam, a novel hypnotic.

The effects on the quantitative EEG and behavior of two doses (0.1 and 0.3 mg) of the novel sedative compound brotizolam were compared to those of 10 mg flurazepam and placebo in a crossover study in 11 normal men. The effects of 0.1 mg brotizolam were equivalent in intensity and duration to those of 10 mg flurazepam, while the 0.3-mg dose of brotizolam was approximately three times as active. The relative physiologic equivalence of doses of brotizolam and flurazepam is 1 to 100. In its EEG profile, brotizolam is classified as a hypnotic-sedative substance. Its suggested use is as a substitute for established benzodiazepines that have hypnotic, sedative, and anticonvulsant activities.

Administration, Oral↗

EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug.

The pharmacologic profile of flutroline, a tetrahydro-gamma-carboline compound, predicts an anti-psychotic compound with greater potency and longer duration than established clinical antipsychotic compounds. In normal male volunteers, it elicited EEG, behavioral, and plasma prolactin release profiles similar to established antipsychotic compounds. Peak activity occurred in 4--5 h. But the clinical activity projected from these studies is one-fifth that of haloperidol. In relation to the available clinical findings, the pharmaco-EEG data are better predictors of the clinical activity of flutroline than its preclinical profile.

Adult↗

EEG and behavioral effects of pirenzepine in normal volunteers.

Effects of pirenzepine on quantitative EEG, heart rate, blood pressure, critical flicker-fusion frequency, vigilance measures, and symptom reports were studied in 23 adult male volunteers under thirty years of age. Oral single doses ranged from 12.5 to 150 mg. Placebo-controlled studies were done in twelve subjects at 100 mg and in ten subjects at 150 mg. Pirenzepine administration was associated with reduced heart rate, dry mouth, and difficulty in focussing near vision. No systematic central activity of the compound was demonstrated at these doses.

Adult↗

CNS effects of the antihistamines diphenhydramine and terfenadine (RMI 9918).

The quantitative EEG profile of a putative antihistaminic drug, terfenadine, was determined in a crossover comparison with diphenhydramine in normal male volunteers. Terfenadine failed to elicit the characteristic EEG or behavioral effects of sedative antihistaminics, and was distinguishable from diphenhydramine. The EEG profile confirmed the lack of CNS effect observed in preclinical and clinical trials.

Adult↗

EEG profile studies of clozapine in volunteers and psychiatric patients.

Among the newer psychoactive compounds, clozapine is classified by some authors as an antipsychotic compound, but it exhibits differences in pharmacology and clinical effects that clearly distinguish it from established antipsychotic compounds. It represents an anomaly in the EEG classification scheme as well. In normal volunteers and in psychotic patients, it elicits EEG effects that are more like those of sedative thymoleptic antidepressants than the established antipsychotic compounds. It is probable that the antipsychotic activity reported by some observers reflected the sedative qualities of the compound and not a prototypic antipsychotic activity. Further testing in other psychiatric populations, particularly patients with depressive illnesses, is warranted.

Adult↗

Phenytoin: EEG effects and plasma levels in volunteers.

The electroencephalographic (EEG) and behavioral effects of oral doses of phenytoin from 100 mg to 1 g in normal male volunteers were measured. The electroencephalogram exhibited decreases in power in the slow frequencies and increases in the fast frequencies, accompanied by an increase in mean frequency. These changes are similar to those seen with psychostimulants. They occurred at average plasma levels of 8 micrograms/ml and above. The time course and the intensity of EEG effects parallel plasma levels. Drug-related EEG changes were bilaterally symmetric. EEG changes at plasma levels of 8--12 micrograms/ml were not associated with behavioral toxic signs. These findings suggest that future psychiatric studies of phenytoin as a psychostimulant should include monitoring for plasma levels, with a minimum of 8 micrograms/ml as a guide to clinical efficacy.

Behavior↗

Clinical study of mianserin, imipramine and placebo in depression: blood level and MHPG correlations.

1. The clinical efficacy of mianserin, a tetracyclic compound, was compared with imipramine and placebo in 47 hospitalized depressed patients. 2. The clinical ratings showed that the three treatment groups improved equivalently during hospitalization. 3. Plasma levels of mianserin correlated with changes in the Hamilton Rating Scale for depression, total score and two of its factors (anxiety/somatization, and retardation) and the item 'late insomnia'. 4. Drowsiness was a more frequent side-effect among mianserin patients on day 4; no other side-effect distinguished the treatments. 5. No relationship between MHPG levels and treatment or treatment outcome were observed.

Adjustment Disorders↗

Electroencephalogram study of mianserin in depressed patients.

1. Electroencephalogram (EEG) recordings and blood level assessments were included in a clinical comparison of the effects of mianserin (GB-94), imipramine and placebo in depressed, hospitalized patients during a 3-week observation period. 2. Temporal changes in behavioural ratings were observed, but these failed to be distinguished among the active drugs and placebo. EEG measures also showed temporal changes, but these also failed to distinguish among the drug conditions, except at 2 h after administration of the first dose. 3. Plasma levels of mianserin were obtained with EEG recordings in a temporal relationship to the behavioural assessments. There were no correlations between the changes in EEG variables and plasma levels of mianserin, or between EEG and behavioural variables, except on acute administration. The lack of discrimination for the EEG variables may be related to the quality of the EEG recordings and the poor control of the temporal relationships of behavioural assessments to EEG recording and drug dosing.

Adolescent↗

EEG, blood level, and behavioral effects of the antidepressant mianserin (ORG GB-94).

A pharmacokinetic analysis of a new antidepressant drug, mianserin (ORG GB-94), was undertaken in 4 male volunteers, each of whom received 15 mg mianserin on two occasions. Plasma levels peak at 2 h with a median level of 11.0 ng/ml, a median beta-phase half-life of 10.0 h, and a median apparent volume of distribution of 3.3 X 10(3) 1. EEG profile analysis shows mianserin to increase frequencies below 6 Hz, decrease those from 7.5 to 15 Hz, and increase frequencies above 18 Hz, a pattern similar to amitriptyline. Peak EEG effects range from 2 to 5 h with a pattern of measured changes that parallels plasma levels with varying latency. Decreases in vigilance measures and in critical flicker-fusion frequency show a similar time course. Mianserin is a putative thymoleptic on EEG profile analysis with high cerebral penetrance.

Animals↗

Acceptance of the rights of homosexuals: a social profile.

The relationships between attitudes toward homosexuality and sociodemographic and attitudinal variables were explored, using the data from a nationwide opinion survey in the United States. Individuals who were willing to grant such rights to homosexuals as teaching in college, speaking in a local community, and removing a book from a local library written by a homosexual and favorable to homosexuality, tended to be well educated, young, Jewish or nonreligious, from urban areas, raised in the Northeast or Pacific states, and willing to provide freedom of expression to people with nonconformist political ideas. "Erotophobia," which was not related closely to the rights issue, was associated with moral judgments about homosexual acts.

Adolescent↗

EEG and task performance after ACTH4-10 in man.

Effects of the heptapeptide ACTH4-10 (Org OI-63) on EEG, some memory tests, and behavior were examined in 12 normal male volunteers under 30 years of age. An intravenous dose of 60 mg was compared to placebo in a Latin square design. EEG was recorded for 2 h after administration of ACTH4-10 or placebo and was quantified by power spectral density analysis. Drug differences were tested by analyses of variance and covariance. No statistical drug effect was seen on the EEG or behavioral measures. Of the psychological tests, only the digit span test showed a decrease in number of errors with ACTH4-10 (p less than or equal to o.05). These results are consistent with previous studies and suggest that an intravenous bolus of ACTH4-10 has a limited effect on the brain function tested.

Adrenocorticotropic Hormone↗

The national sentinel audit for stroke: a tool for raising standards of care.

STUDY OBJECTIVE: To assess the quality of inpatient care and follow-up for stroke in England, Wales and Northern Ireland. DESIGN: Retrospective audit of case notes and service organisation. SETTING: 197 trust (80% of eligible trusts in England, Wales and Northern Ireland). PATIENTS: 6,894 consecutive stroke patients admitted between 1 January 1998 and 31 March 1998 (up to 40 per trust). AUDIT TOOL: The Intercollegiate Stroke Audit. RESULTS: Most patients were admitted to acute hospitals with access to the appropriate acute investigations and treatments. Only 64% of trusts had a physician with responsibility for stroke and only 50% had a stroke team. Involvement of different members of the multidisciplinary team within appropriate time-frames varied from 37% to 61%. Assessment of impairments specific to stroke was inadequate (screening for swallowing disorders in only 55%, cognitive function tests in 23% and visual field examination in 44%). Rehabilitation goals were agreed by the multidisciplinary team in only 55% of eligible cases. 41% of patients were contacted by their GP within 3 days of discharge. The best compliance with standards was achieved for the 18% of patients who spent at least 50% of their time in a stroke unit. CONCLUSIONS: This national audit demonstrates that care is suboptimal in many areas, and that there is wide variation in standards for the management of stroke across the country. This may have implications for clinical governance.

Aftercare↗